| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥34.59B | +1.8% |
| Gross profit | ¥8.96B | — |
| Operating income | ¥5.74B | — |
| Net income | ¥5.24B | +29.8% |
| Gross margin | 25.9% | Net margin 15.2% |
| Revenue Q/Q | -13.5% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥25.62B | 74.1% |
| R&D | ¥0.26B | 0.8% |
| SG&A | ¥3.26B | 9.4% |
| Tax & other | ¥0.50B | 1.4% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
复星医药 ・ 南山铝业 ・ 海航控股 ・ 圆通速递 ・ 恒瑞医药 ・ 万华化学 ・ 恒力石化 ・ 江西铜业 ・ 中航机载 ・ 国电南瑞 ・ 小商品城 ・ 华鲁恒升
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies